Pfizer said on Nov. 5 that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90%.
Pfizer said on Nov. 5 that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90%.